Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of tildacerfont in adults with classic congenital adrenal hyperplasia
NL-OMON60117Phase 2Completed
- Sponsor
- Spruce Biosciences, Inc.
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in classic congenital adrenal hyperplasia comparing Tildacerfont with Placebo (2 arms). Primary endpoint: Percent change from baseline in androstenedione after 12 weeks on treatment. Started Jan 2021; status: completed.
02
Drugs
tildacerfont
03
Conditions
classic congenital adrenal hyperplasia
Beyond the preview
Go deeper on NL-OMON60117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60117.